| A cyclometallated iridium(III) complex as a c-myc G-quadruplex stabilizer and down-regulator of c-myc oncogene expression. | None |
| Structure-based design of flavone derivatives as c-myc oncogene down-regulators. | None |
| results redefine the physiological relationship between Mnt and Myc and requirements for Myc-driven oncogenesis | None |
| Antiproliferative protein Tob directly regulates c-myc proto-oncogene expression through cytoplasmic polyadenylation element-binding protein CPEB. | None |
| The role of the proto-oncogene c-myc in B lymphocyte differentiation. | None |
| Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of DeltaEGFR/EGFRvIII. | None |
| Transcriptional regulation of target genes by association with gene regulatory chromatin in cooperation with c-Myc by nuclear DeltaEGFR makes a unique contribution to its oncogenicity. | None |
| To further understand how c-Myc switches from an oncogenic protein to an apoptotic protein, we examined the mechanism of p53-independent c-Myc-induced apoptosis. | None |
| we induced tumors in mice via the injection of transposons encoding three oncogenes(HRAS, c-Myc and shp53) and a plasmid-expressing transposase. | None |
| results therefore suggest that c-MYC induces stress-mediated activation of ATF2 and ATF7 and that these transcription factors regulate apoptosis in response to oncogenic transformation of B cells | None |
| metastatic conversion of KrasG12D-expressing cells that exhibit different degrees of differentiation and malignancy can be reconstructed in cell culture, and the proto-oncogene c-Myc controls the generation of self-renewing metastatic cancer | None |
| Characterization of MYC-induced tumorigenesis by in situ lipid profiling. | None |
| It provides a strategy to define a precise molecular picture at a resolution of about 200 mum that may be useful in identifying lipid molecules that define how the MYC oncogene initiates and maintains tumorigenesis. | None |
| ING4 inhibits the translation of proto-oncogene MYC by interacting with AUF1. | None |
| Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression. | None |
| c-Myc oncogene expression in selected odontogenic cysts and tumors: An immunohistochemical study. | None |
| PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. | None |
| A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy. | None |
| Synergistic effect of the v-myc oncogene with H-ras on radioresistance. | None |
| Expression of c-myc oncogene during differentiation of human burst-forming unit, erythroid (BFU-E). | None |